Premier Alternatives

Iaso Therapeutics

East Lansing, MI · Founded 2018 · Privately Held (backing)

Operator of synthetic antigen-based vaccines designed to prevent and treat infectious diseases. Iaso Therapeutics is based in East Lansing, MI and was founded in 2018. Its last reported valuation was $5.3 million in Jan 2023. It has raised $1.8 million across 2 recorded rounds; the latest was a $570,000 seed round in Jan 2026.

Last reported valuation
$5.3M
Oct 2026
Priced at
—
Total raised
$1.8M
Last round
Seed Round
Jan 2026

Iaso Therapeutics key facts

as of Oct 2026
  • Operator of synthetic antigen-based vaccines designed to prevent and treat infectious diseases.
  • Iaso Therapeutics is valued at approximately $5.3M as of Oct 2026 (last reported valuation).
  • It has raised $1.8M across 2 recorded rounds; the latest was Seed Round ($570K) in Jan 2026.
  • Notable investors include US National Science Foundation, Michigan Rise, Apjohn Group, Biosciences Research and Commercialization Center, National Institute Of Allergy and Infectious Diseases — 6 tracked in total.
  • Iaso Therapeutics has filed 1 Form D with the SEC, most recently Jan 2023 ($438K sold to 5 investors).
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$5.3M

Iaso Therapeutics's last reported valuation, Jan 2023. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Free account
More of Iaso Therapeutics with a free account
  • ·Watch Iaso Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Iaso Therapeutics funding rounds

2 rounds
Jan 2026Seed Round$570KSEC filing▮
Dec 2022Seed Round$438KSEC filing▮
Full funding history →

Iaso Therapeutics valuation

Iaso Therapeutics's last reported valuation was $5.3 million in Jan 2023. No priced round, secondary trade or fund mark has surfaced since.

How much has Iaso Therapeutics raised?

Iaso Therapeutics has raised $1.8 million in total; 2 of its rounds are on record. The largest on record was a $570,000 seed round in Jan 2026.

Iaso Therapeutics has filed 1 Form D with the SEC, most recently in Jan 2023 ($437,850 sold to 5 investors).

Iaso Therapeutics investors

6 investors are on record for Iaso Therapeutics, including US National Science Foundation, Michigan Rise, Apjohn Group and Biosciences Research and Commercialization Center. The seed round in Jan 2026 drew 1 investor.

About Iaso Therapeutics

Operator of synthetic antigen-based vaccines designed to prevent and treat infectious diseases. The company offers a platform integrating precision-engineered antigens with a virus-like particle carrier providing strong immunogenicity, extensive conjugation capacity, and controlled synthetic design, enabling healthcare providers and research institutions to accelerate vaccine development, expand immune coverage, and improve durability against emerging pathogens.

Sector
Healthcare
HQ
East Lansing, MI, United States
Founded
2018
Employees
4
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.